Phase II Trial of ZD1839 (IRESSA) [gefitinib] and Pegylated Interferon Alfa 2b (PEG-Intron) in Unresectable or Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2017
At a glance
- Drugs Gefitinib (Primary) ; Peginterferon alfa-2b
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 30 Jan 2017 Status changed from completed to discontinued.
- 14 Jun 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.